北京德恒律师事务所 关于中红普林医疗用品股份有限公司 2026 年第一次临时股东会的 法律意见 北京市西城区金融街 19 号富凯大厦 B 座 12 层 电话:010-52682888 传真:010-52682999 邮编:100033 北京德恒律师事务所 关于中红普林医疗用品股份有限公司 2026 年第一次临时股东会的法律意见 北京德恒律师事务所 关于中红普林医疗用品股份有限公司 2026 年第一次临时股东会的 法律意见 德恒 01G20250295-05 号 致：中红普林医疗用品股份有限公司 中红普林医疗用品股份有限公司（以下简称"公司"）2026 年第一次临时 股东会（以下简称"本次会议"）于 2026 年 2 月 5 日（星期四）召开。北京德 恒律师事务所（以下简称"德恒"）受公司委托，指派崔满长律师、王瑞芸律师 （以下简称"德恒律师"），根据《中华人民共和国证券法》（以下简称"《证 券法》"）、《中华人民共和国公司法》（以下简称"《公司法》"）、中国证 券监督管理委员会《上市公司股东会规则》（以下简称"《股东会规则》"）、 《中红普林医疗用品股份有限公司章程》（以下简称"《公司章程》"）的规定， 就本 ...

Core Viewpoint - Zhonghong Medical is experiencing growth in its stock performance and is positioned to benefit from various market trends, including the pet economy and digital transformation in healthcare [1][2][4]. Group 1: Company Overview - Zhonghong Medical specializes in the research, production, and sales of high-quality disposable protective gloves, with a revenue composition of 89.48% from health protection products, 6.22% from safety infusion products, and 4.30% from innovative incubation products [9]. - The company was established on December 22, 2010, and went public on April 27, 2021, with its headquarters located in Tangshan, Hebei Province [9]. - As of September 30, 2025, Zhonghong Medical reported a revenue of 1.864 billion yuan, reflecting a year-on-year growth of 1.38%, while the net profit attributable to shareholders was -7.21 million yuan, a decrease of 114.13% compared to the previous year [10]. Group 2: Market Position and Trends - The company primarily focuses on export sales, utilizing an ODM direct sales model, where it produces medical devices and consumables for overseas brand owners [2]. - Zhonghong Medical's overseas revenue accounted for 81.56% of its total revenue, benefiting from the depreciation of the Chinese yuan [4]. - The company is recognized as a state-owned enterprise, with its ultimate control held by the State-owned Assets Supervision and Administration Commission of the Xiamen Municipal Government [5]. Group 3: Product Innovations and Developments - At the 12th Beijing Pet Expo, Zhonghong Medical showcased its innovative veterinary infusion pumps, which feature IP34 waterproof design and dual CPU architecture, catering to various clinical scenarios [2]. - The company emphasizes innovation through digital technology integration, aiming to develop high-quality, innovative medical consumables and equipment [3].

Summary of Key Points from the Conference Call Industry Overview - The report focuses on the commercial aerospace industry, highlighting the transition into a second phase of investment with a significant acceleration in fundamentals exceeding expectations [1][4]. Core Insights and Arguments - The T/S orders, domestic satellite constellations, and rocket launch progress have become unexpectedly critical elements in determining investment opportunities [1][5]. - The current market perception is misaligned, as it continues to extrapolate launch volumes linearly, while the demand for space computing power suggests a need for a more nuanced approach, projecting a requirement of 5-10 GW for mid-term outlooks [5]. - This translates to a forecast of tens of thousands of satellites and nearly 10,000 rocket launches annually, with a vision of one million units of embodied intelligence per year [5]. Investment Opportunities - Leading companies such as Feiwo Technology, Western Materials, and Aerospace Power are identified as having strong cost-performance advantages, warranting increased attention [6][9]. - The SpaceX plan for a million-satellite system emphasizes the importance of solar energy utilization, positioning communication satellites and computing satellites as vehicles for advancing civilization through photonic conversion [6]. - The domestic photovoltaic industry is expected to benefit significantly from the demand for space photovoltaic applications, leading to an expansion of overseas production capacity and a rise in the scale of specialized products distinct from terrestrial needs [6]. Market Dynamics - The upstream segment, particularly in engine materials, is expected to see changes in demand for scarce metals as rocket demand increases [7]. - The midstream equipment sector is experiencing significant marginal changes, particularly in engines and 3D printing, driven by scarcity and long-term inflationary logic [7]. - The downstream segment is witnessing accelerated progress among listed companies, with a focus on resolving capacity bottlenecks in the commercial rocket sector, indicating a potential for exceeding production expectations [8]. Strategic Developments - The report notes the acceleration of the space race, with a focus on core positioning in rockets and satellites, particularly in light of SpaceX's application for a million-satellite constellation and the establishment of an orbital AI data center network [10][12]. - The Chinese government is pushing for breakthroughs in the aerospace sector, with plans announced for the construction of a "Rocket Star City" in Shanghai, aiming for an annual production capacity of 80 rockets and 200 satellites by 2027, and 150 rockets and 500 satellites by 2030 [11]. Additional Considerations - The report suggests monitoring developments in laser communication as a potential area of growth [13]. - The challenges posed by the scale of a million-satellite system to existing space traffic management rules and the need for stringent collision avoidance standards are highlighted as critical sustainability considerations [14][15].

Group 1 - The core viewpoint of the article highlights that Zhonghong Medical (300981) is facing significant financial challenges, with a projected net loss for 2025 ranging from 130.5 million to 87 million yuan [1][3] - The expected net profit, excluding non-recurring losses, is projected to be between 186.5 million and 124.5 million yuan, primarily impacted by the protective glove industry's cyclical nature, price fluctuations, and currency exchange rates [1][3] - The company anticipates asset impairment provisions, including fixed assets and inventory, amounting to approximately 27 million to 41 million yuan, and goodwill impairment provisions of about 58 million to 88 million yuan [1][3] Group 2 - On January 30, 2026, Zhonghong Medical's stock closed at 12.77 yuan, down 1.39%, with a turnover rate of 0.86% and a trading volume of 33,800 shares, resulting in a transaction amount of 42.9834 million yuan [1] - The main capital flow on January 30 showed a net outflow of 2.7059 million yuan from institutional investors and a net inflow of 2.9078 million yuan from retail investors [1][3] - The company announced that its subsidiary, Beijing Linpu Medical Supplies Co., Ltd., has opened a special account for raised funds at Bank of Hangzhou's Beijing branch and signed a regulatory agreement to ensure proper management of the raised funds [1][3]

中红普林医疗用品股份有限公司 关于公司子公司开立募集资金专项账户 证券代码：300981 证券简称：中红医疗 公告编号：2026- 011 并签订监管协议的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 一、募集资金基本情况 经中国证券监督管理委员会《关于同意中红普林医疗用品股份有限公司首 次公开发行股票注册的批复》（证监许可[2021]758 号）同意注册，中红普林 医疗用品股份有限公司（以下简称"公司"）首次公开发行人民币普通股（A 股）股票 41,670,000 股，每股面值 1.00 元，发行价为每股人民币 48.59 元， 募集资金总额为人民币 2,024,745,300.00 元，扣除发行费用总额（不含增值税） 人民币 128,288,946.26 元，实际募集资金净额为人民币 1,896,456,353.74 元， 扣除募投项目需要使用募集资金后超募资金为 1,316,713,653.74 元。募集资金 已于 2021 年 4 月 21 日到账至公司指定账户，容诚会计师事务所（特殊普通合 伙）对公司首次公开发行股票的资金到位情况进行了审验， ...

Core Viewpoint - Zhonghong Medical (300981) is expected to report significant losses for the fiscal year 2025, primarily due to industry cycles, currency fluctuations, and asset impairments [1][3]. Trading Information Summary - On January 29, Zhonghong Medical closed at 12.95 yuan, down 1.89%, with a turnover rate of 0.99%, a trading volume of 38,800 shares, and a transaction value of 50.41 million yuan [1]. - On the same day, the main funds experienced a net outflow of 5.04 million yuan, while retail investors saw a net inflow of 4.97 million yuan [1][3]. Performance Disclosure Highlights - Zhonghong Medical forecasts its total revenue for 2025 to be between 2.097 billion yuan and 2.726 billion yuan [1]. - The company anticipates a net profit loss attributable to shareholders ranging from 87 million yuan to 130 million yuan, with a non-recurring net profit loss expected to be between 125 million yuan and 186 million yuan [1][3]. Company Announcement Summary - The 2025 annual performance forecast indicates a net profit loss of 130.5 million yuan to 87 million yuan, significantly impacted by the protective glove industry's cyclical nature, exchange rate changes, and various asset impairments totaling approximately 27 million yuan to 41 million yuan for fixed assets and inventory, and 58 million yuan to 88 million yuan for goodwill [1][3].

证券之星消息，中红医疗发布业绩预告，预计2025年全年扣非后净利润亏损1.25亿元至1.86亿元。 公告中解释本次业绩变动的原因为： 1、报告期内,防护手套类产品行业周期及价格波动,以及人民币对美元升值等因素对公司业绩产生较大影 响。2、报告期内,公司结合行业发展、市场变化及经营情况,对部分出现减值迹象的固定资产、存货计提 减值准备合计约0.27亿元至0.41亿元,最终减值金额以会计师事务所审计数据为准。3、本报告期末,公司 聘请的评估机构,对公司收购桂林恒保健康防护有限公司(以下简称"恒保健康")所形成的商誉进行了初步 评估和测算。结合行业发展、市场变化和实际经营情况等因素,判断恒保健康所形成的商誉出现减值迹 象。为更加客观、公正地反映公司的财务状况和资产价值,根据《企业会计准则第8号-资产减值》等相 关会计政策规定,按照谨慎性原则,预计计提商誉减值准备金额约0.58亿元至0.88亿元,最终计提商誉减值 准备金额需根据评估机构的评估报告及会计师事务所审计数据确定。4、报告期内,预计非经常性损益对 归属于上市公司股东的净利润的影响金额合计约0.38亿元至0.75亿元,主要系理财收益、政府补助等所 致。 中红医 ...

Core Viewpoint - Zhonghong Medical is expected to report a net profit loss of between 87 million to 130 million yuan for the full year of 2025 due to various factors impacting its performance [1] Group 1: Performance Forecast - The company attributes the expected performance decline to industry cycle and price fluctuations in the protective glove sector, as well as the appreciation of the RMB against the USD [1] - The company plans to recognize impairment provisions for fixed assets and inventory totaling approximately 27 million to 41 million yuan due to signs of impairment [1] - An initial assessment of goodwill related to the acquisition of Guilin Hengbao Health Protection Co., Ltd. indicates potential impairment, with expected provisions of about 58 million to 88 million yuan [1] - Non-recurring gains and losses are anticipated to impact the net profit attributable to shareholders by approximately 38 million to 75 million yuan, mainly from investment income and government subsidies [1] Group 2: Q3 Financial Results - For the first three quarters of 2025, the company's main revenue reached 1.864 billion yuan, a year-on-year increase of 1.38% [2] - The net profit attributable to shareholders was -7.21 million yuan, a year-on-year decrease of 114.13% [2] - The company's net profit after deducting non-recurring items was -37.34 million yuan, a significant year-on-year decline of 20,229.69% [2] - In Q3 2025, the company reported a single-quarter main revenue of 626 million yuan, a year-on-year decrease of 9.24% [2] - The single-quarter net profit attributable to shareholders was -12.95 million yuan, a year-on-year decrease of 170.01% [2] - The single-quarter net profit after deducting non-recurring items was -24.17 million yuan, a year-on-year decline of 691.19% [2] - The company's debt ratio stood at 28.02%, with investment income of 8.76 million yuan and financial expenses of -17.67 million yuan, while the gross profit margin was 10.54% [2]

Core Viewpoint - Zhonghong Medical (300981.SZ) expects a net profit attributable to shareholders of the listed company to be between -130.5 million and -87 million yuan for 2025, compared to -87.13 million yuan in the same period last year [1] Group 1: Financial Performance - The net profit after deducting non-recurring gains and losses is projected to be between -186.5 million and -124.5 million yuan [1] - The company reported a significant impact on its performance due to the cyclical nature and price fluctuations in the protective glove industry, as well as the appreciation of the RMB against the USD [1] Group 2: Asset Impairment - During the reporting period, the company recognized impairment provisions for fixed assets and inventory totaling approximately 27 million to 41 million yuan due to signs of impairment [1] - The final impairment amount will be determined based on the audit data from the accounting firm [1]

Group 1 - The company expects a net profit attributable to shareholders for the year 2025 to be between -130 million and -87 million yuan, with a net profit excluding non-recurring gains and losses projected to be between -186 million and -125 million yuan [1] - The performance of the company is significantly impacted by the cyclical nature and price fluctuations in the protective glove industry, as well as the appreciation of the RMB against the USD [1]